R&D Trends

Adimab, Celgene collaborate for antibody discovery

Wednesday, August 21, 2013 10:22 AM

Adimab, a technology company focuses on the discovery of fully human antibodies, has announced a multi-target discovery collaboration with Celgene of Summit, NJ. Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

More... »

ACRP, ACRES collaborate to improve clinical research conduct

Monday, August 19, 2013 11:48 AM

The Association of Clinical Research Professionals (ACRP) and the Alliance for Clinical Research Excellence and Safety (ACRES) are collaborating to address challenges facing the clinical research enterprise globally and to improve medical product development and delivery worldwide.

More... »

HR+Survey Solutions CRO study finds high employee turnover rate

Friday, August 16, 2013 01:38 PM

According to the 14^th annual CRO Industry Global Compensation and Turnover Survey, conducted by HR+Survey Solutions, a compensation and research firm, CRO employees are leaving for new jobs at higher rates than their counterparts in other industries.

More... »

NIH awards Seattle BioMed $16.6 million tuberculosis grant

Friday, August 16, 2013 12:04 PM

Seattle BioMed, a U.S. independent nonprofit focused solely on infectious disease research, has been awarded a grant from the National Institute of Allergy and Infectious Diseases, part of the NIH, which will take a comprehensive systems approach to tuberculosis (TB) infection, harnessing the power of technology and systems biology to examine the progression from latent infection to disease. The grant will total up to $16.6 million over a five-year period.

More... »

Theorem, RadMD collaborate

Friday, August 16, 2013 11:44 AM

Theorem Clinical Research is collaborating with RadMD, a medical imaging company.

More... »

Ligand, CURx enter global license agreement

Friday, August 16, 2013 11:20 AM

Ligand Pharmaceuticals has entered a global license agreement with CURx Pharmaceuticals for the development and commercialization of Ligand's Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible to receive more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%.

More... »

Avanir, Merck announce diabetes co-promotion agreement

Thursday, August 15, 2013 12:30 PM

Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the U.S.

More... »

Sanford-Burnham, Pfizer collaborate

Thursday, August 15, 2013 11:14 AM

Sanford-Burnham Medical Research Institute has signed a three-year collaboration agreement with Pfizer to identify therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering therapeutic strategies for reducing insulin resistance in obesity and diabetes.

More... »

Amgen, Servier complete product collaboration

Thursday, August 15, 2013 09:30 AM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced  July 8, completing the transaction.

More... »

University of Maryland Ventures partners with life sciences companies

Thursday, August 15, 2013 09:02 AM

University of Maryland (UM) Ventures has announced agreements between University of Maryland, Baltimore (UMB) and five different life sciences companies across the Baltimore/Washington metropolitan region: Rexahn Pharmaceuticals, Plasmonix, IGI Technologies, A&G Pharmaceuticals and BioAssay Works.

More... »